Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00567567 · OUTCOME

Topotecan Systemic Clearance

Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma · Source last updated 2022-04-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
L/h/m2
Interval / dispersion
Full Range
Time frame
Day 1 of courses 1-2

What was measured

Median topotecan systemic clearance for courses 1 and 2.

Analysis population: Eligible patients evaluated for topotecan systemic clearance.

Groups in this outcome

Single HST (CEM)

Induction therapy + single myeloablative consolidation

Tandem HST (CEM), Randomly Assigned

Induction therapy + tandem myeloablative consolidation

Not Assigned

Patients that either failed during Induction therapy or refused randomization

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Single HST (CEM)82
Tandem HST (CEM), Randomly Assigned76
Not Assigned103

Reported measurements

Source class 1
Values in L/h/m2 · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Single HST (CEM)28.1Not reported14.949.4Not reported
Tandem HST (CEM), Randomly Assigned28.1Not reported11.642.7Not reported
Not Assigned28.5Not reported16.354.7Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        14.9
        upper Limit
        49.4
        value
        28.1
      2. group Id
        OG001
        lower Limit
        11.6
        upper Limit
        42.7
        value
        28.1
      3. group Id
        OG002
        lower Limit
        16.3
        upper Limit
        54.7
        value
        28.5
denoms
  1. counts
    1. group Id
      OG000
      value
      82
    2. group Id
      OG001
      value
      76
    3. group Id
      OG002
      value
      103
    units
    Participants
description
Median topotecan systemic clearance for courses 1 and 2.
dispersion Type
Full Range
groups
  1. description
    Induction therapy + single myeloablative consolidation
    id
    OG000
    title
    Single HST (CEM)
  2. description
    Induction therapy + tandem myeloablative consolidation
    id
    OG001
    title
    Tandem HST (CEM), Randomly Assigned
  3. description
    Patients that either failed during Induction therapy or refused randomization
    id
    OG002
    title
    Not Assigned
param Type
MEDIAN
population Description
Eligible patients evaluated for topotecan systemic clearance.
reporting Status
POSTED
time Frame
Day 1 of courses 1-2
title
Topotecan Systemic Clearance
type
SECONDARY
unit Of Measure
L/h/m2

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice